This disease affects approximately 280 million people worldwide. RNAi therapy provides new treatment ideas

Dicerna Pharmaceuticals announced today that the company's research RNAi therapy DCR-AUD has completed the first batch of subjects in a phase 1 clinical trial for the treatment of patients with alcohol use disorder (AUD)
.

Alcohol use disorder is a chronic disease characterized by the inability to stop or control alcohol use despite social, occupational, or health consequences
.

DCR-AUD is a GalXC RNAi drug candidate developed by Dicerna, which aims to silence the expression of mRNA encoding acetaldehyde dehydrogenase 2 (ALDH2) in the liver
.

Dicerna designed DCR-AUD based on human genetic data, showing that knocking out ALDH2 mRNA in AUD individuals may provide similar physiological feedback, thereby preventing harmful levels of alcohol consumption
.

Image source: Dicerna's official website

This study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of DCR-AUD in healthy volunteers
.

Reference materials:

[1] Dicerna Initiates Phase 1 Clinical Trial of DCR-AUD, a Novel Investigational GalXC™ RNAi Therapeutic Candidate for the Treatment of Alcohol Use Disorder.

(The original text has been deleted)